# Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease

> **NCT00277810** · PHASE2,PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 250 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** lecozotan SR (SRA-333)

## Key facts

- **NCT ID:** NCT00277810
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2020-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00277810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00277810, "Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00277810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*